RxDoctor Payments Data

Charles Latham, DO

Family Medicine · Forest, VANPI 1780064501

Payments from drug & device makers

$9,802in general payments, 2019–2025

Across 636 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Boehringer Ingelheim$778
  • Pfizer$699
  • Lilly USA, LLC$573
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$9,789100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,802 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$445,766
Medicare patients
518
Services billed
14,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$123,664
FarxigaDapagliflozin Propanediol139$121,005
EliquisApixaban108$111,230
JanuviaSitagliptin Phosphate74$77,693
OzempicSemaglutide51$69,120
RybelsusSemaglutide35$45,544
XareltoRivaroxaban36$40,765
TradjentaLinagliptin42$37,104
LinzessLinaclotide33$29,294
Repatha SureclickEvolocumab22$24,912
TrulicityDulaglutide19$18,583
Spiriva HandihalerTiotropium Bromide12$13,939
SymbicortBudesonide/Formoterol Fumarate20$11,564
Breo ElliptaFluticasone/Vilanterol11$8,728
JanumetSitagliptin Phos/Metformin Hcl15$8,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$778$160,768139 claims
AstraZenecaFarxiga, Symbicort$1,469$132,569159 claims
Novo NordiskOzempic, Rybelsus$1,797$114,66486 claims
PfizerEliquis$699$111,230108 claims
MerckJanuvia, Janumet$96$86,18689 claims
Johnson & JohnsonXarelto$118$40,76536 claims
AbbVieLinzess, Synthroid$1,276$31,85175 claims
Lilly USA, LLCTrulicity$573$18,58319 claims
GSKBreo Ellipta$401$8,72811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Forest

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →